Thibaut Mongon Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 4 weeks ago
Thibaut Mongon has an estimated net worth of at least $22.9 million*, as of March 12, 2025. They own shares of JNJ stock. They have sold 69,801 shares of JNJ stock since 2021, for an estimated $12.1 million.
Thibaut Mongon $JNJ SEC Form 4 Insider Trading
Thibaut Mongon has filed a total of 39 insider trades in $JNJ since 2021. Their most recent trade was a sale of 16,953 shares, made on Nov 04, 2022. Their largest trade was a sale of 18,293 shares, made on Nov 04, 2022. We estimate that they now own shares of $JNJ, worth an estimated $10.7 million.
Insider Trading at $JNJ
There have been a total of 350 insider trades reported at $JNJ since 2021, with 1,000 shares purchased and 657,475 shares sold. The most active insider traders in $JNJ stock have been Peter Fasolo, Thibaut Mongon, and William Hait. The most recent trade was a sale of 6,999 shares reported by Robert J Decker (VP Corporate Controller), made on Feb 25, 2025.
History of Insider Stock Trades by Thibaut Mongon
Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
---|---|---|---|---|
![]() |
Sale | 16,953 | Nov 04, 2022 | Nov. 8, 2022, 5:59 p.m. |
![]() |
Sale | 18,293 | Nov 04, 2022 | Nov. 8, 2022, 5:59 p.m. |
![]() |
Sale | 1,735 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 1,757 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 1,856 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 1,420 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 2,944 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 3,770 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 6,566 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 1,976 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 1,657 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 200 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 227 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 373 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 464 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 477 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 487 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 550 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 551 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 555 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 596 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 597 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 613 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 717 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 833 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 848 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 957 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 1,103 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 157 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 6 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 9 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 10 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 45 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 45 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 57 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 97 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 100 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 143 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
![]() |
Sale | 57 | Mar 17, 2022 | March 21, 2022, 4:38 p.m. |
$JNJ Executives and Stock Owners with Insider Trades
-
Peter Fasolo, Exec VP, Chief HR Officer
-
Thibaut Mongon, Exec VP, WW Chair, Consumer
-
William Hait, See Remarks
-
Kathryn E Wengel, EVP, Chief GSC Officer
-
Joseph J Wolk, Exec VP, CFO
-
Robert J Decker, Controller, CAO
-
Ashley Mcevoy, EVP, WW Chair, MedTech
-
Jennifer L Taubert, EVP, WW Chair, Pharmaceuticals
-
Robert J Decker, VP Corporate Controller
-
James D. Swanson, See Remarks
-
Kathryn E Wengel, EVP, Chief TO and Risk Officer
-
Timothy Schmid, EVP, WW Chair, MedTech
-
Vanessa Broadhurst, EVP, Global Corp Affairs
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.